New trends in the neurobiology and pharmacology of affective disorders

Pharmacological Reports

Volumn 65, Issue 6, 2013, Pages 1441-1450

  Lasoñ, Wladyslaw ^a   Budziszewska, Boguslawa ^a   Basta Kaim, Agnieszka ^a   Kubera, Marta ^a   Maes, Michael ^b  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

^b Maes Clinics at TRIA   (Thailand)

Author keywords

Animal models; Comorbidity; Depression; Immunity; Neurodevelopment

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; DESIPRAMINE; FLUOXETINE;

ANTIDEPRESSANT ACTIVITY; BEHAVIOR CHANGE; BIOLOGICAL MODEL; BRAIN FUNCTION; COMORBIDITY; CONTACT ALLERGY; DEPRESSION; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG MARKETING; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG TARGETING; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE RESPONSE; LOW DRUG DOSE; MOOD DISORDER; NERVE CELL PLASTICITY; NERVOUS SYSTEM DEVELOPMENT; NEUROBIOLOGY; NONHUMAN; REVIEW; TREND STUDY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; DEPRESSION; HUMANS; MOOD DISORDERS;

EID: 84894210520     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71504-4     Document Type: Article

References (41)

1. Amsterdam JD, Hornig-Rohan M: Treatment algorithms in treatment-resistant depression. Psychiatry Clin North Am, 1996, 19, 371-386. (Pubitemid 26184108)
2. Anderson G, Kubera M, Duda W, Lasoñ W, Berk M, Maes M: Increased IL-6 trans-signaling in depression: Focus on the tryptophan catabolite pathway, melatonin and neuroprogression. Pharmacol Rep, 2013, 65, 1647-1654.
3. Carlezon WA Jr, Mague SD, Andersen SL: Enduring behavioral effects of early exposure to methylphenidate in rats. Biol Psychiatry, 2003, 54, 1330-1337. (Pubitemid 37522156)
4. Chocyk A, Majcher-Maoelanka I, Dudys D, Przyborowska A, Wêdzony K: Impact of early-life stress on the medial prefrontal cortex functions-a search for the pathomechanisms of anxiety and mood disorders. Pharmacol Rep, 2013, 65, 1462-1470.
5. Curzytek K, Kubera M, Szczepanik M, Basta-Kaim A, Leoekiewicz M, Budziszewska B, Lasoñ W, Maes M: Crosstalk between contact hypersensitivity reaction and antidepressant drugs. Pharmacol Rep, 2013, 65, 1673-1680.
6. Darras VM: Endocrine disrupting polyhalogenated organic pollutants interfere with thyroid hormone signaling in the developing brain. Cerebellum, 2008, 26-37.
7. Detka J, Kurek A, Basta-Kaim A, Kubera M, LasoñW, Budziszewska B: Neuroendocrine link between stress, depression and diabetes. Pharmacol Rep, 2013, 65, 1591-1600.
8. Doze VA, Handel EM, Jensen KA, Darsie B, Luger EJ, Haselton JR, Talbot JN, Rorabaugh BR: A1A-and a1B-adrenergic receptors differentially modulate antidepressant-like behavior in the mouse. Brain Res, 2009, 1285, 148-157.
9. Faron-Górecka A, Kuoemider M, Solich J, Kolasa M, Szafran K, Zurawek D, Pabian P, Dziedzicka-Wasylewska M: Involvement of prolactin and somatostatin in depression and the mechanism of action of antidepressant drugs. Pharmacol Rep, 2013, 65, 1640-1646.
10. Filip M, Frankowska M, Jastrzêbska J, Wydra K, Przegaliñski E: Preclinical studies on comorbidity between depression and psychostimulant addiction. Pharmacol Rep, 2013, 65, 1529-1534.
11. Gadek-Michalska A, Tadeusz J, Rachwalska P, Bugajski J: Cytokines, prostaglandins and nitric oxide in the regulation of stress-response systems. Pharmacol Rep, 2013, 65, 1655-1662.
12. Haduch A, Bromek E, Daniel WA: Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters. Pharmacol Rep, 2013, 65, 1519-1528.
13. Hoyer S, Lannert H: Long-term effects of corticosterone on behavior, oxidative and energy metabolism of parietotemporal cerebral cortex and hippocampus of rats: Comparison to intracerebroventricular streptozotocin. J Neural Transm, 2008, 115, 1241-1249.
14. Kajta M, Wójtowicz A: Impact of endocrine-disrupting chemicals on neural development and the onset of neurological disorders. Pharmacol Rep, 2013, 65, 1632-1639.
15. Kreiner G, Chmielarz P, Roman A, Nalepa I: Gender differences in genetic moue models evaluated for depressive-like and antidepressant behavior. Pharmacol Rep, 2013, 65, 1580-1590.
16. Magariños AM, McEwen BS: Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc Natl Acad Sci USA, 2000, 97, 11056-11061.
17. Mika J, Osikowicz M, Rojewska E, Korostynski M, Wawrzczak-Bargiela A, Przewlocki R, Przewlocka B: Differential activation of spinal microglial and astroglial cells in a mouse model of peripheral neuropathic pain. Eur J Pharmacol, 2009, 623, 65-72.
18. Mika J, Zychowska M, MakuchW, Rojewska E, Przewlocka B: Neuronal and immunological basis of action of antidepressants in chronic pain-clinical and experimental studies. Pharmacol Rep, 2013, 65, 1611-1621.
19. Nalepa I, Kreiner G, Bielawski A, Rafa-Zablocka K, Roman A: α-Adrenergic receptor subtypes in the central nervous system: Insights from genetically engineered moue models. Pharmacol Rep, 2013, 65, 1489-1497.
20. Nikiforuk A, Popik P: Neurochemical modulation of stress-induced cognitive inflexibility in a rat model of an attentional set-shifting task. Pharmacol Rep, 2013, 65, 1479-1488.
21. Ossowska K, Lorenc-Koci E: Depression in Parkinson's disease. Pharmacol Rep, 2013, 65, 1545-1557.
22. Palucha-Poniewiera A, Wieroñska JM, Brañski P, Burnat G, Chruoecicka B, Pilc A: Is the mGlu5 receptor a possible target for new antidepressant drugs? Pharmacol Rep, 2013, 65, 1506-1511.
23. Pan Y, Hong Y, Zhang QY, Kong LD: Impaired hypothalamic insulin signaling in CUMS rats: Restored by icariin and fluoxetine through inhibiting CRF system. Psychoneuroendocrinology, 2013, 38, 122-134.
24. Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P: Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology, 2010, 75, 1920-1927.
25. Remy P, Doder M, Lees A, Turjanski N, Brooks D: Depression in Parkinson's disease: Loss of dopamine and noradrenaline innervation in the limbic system. Brain, 2005, 128, 1314-1322. (Pubitemid 40826185)
26. Rogóz Z: Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: Preclinical and clinical efficacy. Pharmacol Rep, 2013, 65, 1535-1544.
27. Roman A, Kreiner G, Nalepa I: Macrophages and depression-A misalliance or well-arranged marriage? Pharmacol Rep, 2013, 65, 1663-1672.
28. Siwek M, Sowa-Kuæma M, Dudek D, Styczeñ K, Szewczyk B, Kotarska K, Misztak P et al.: Oxidative stress markers in affective disorders. Pharmacol Rep, 2013, 65, 1558-1571.
29. Siwek M, Szewczyk B, Dudek D, Styczeñ K, Sowa-KuæmaM, Mlyniec K, Siwek K et al.: Zinc as a marker of affective disorders. Pharmacol Rep, 2013, 65, 1512-1518.
30. Skuza G: Ethanol withdrawal-induced depressive symptoms in animals and therapeutic potential of sigma1 receptor ligands. Pharmacol Rep, 2013, 65, 1681-1687.
31. Szafran K, Faron-Górecka A, Kolasa M, Kuoemider M, Solich J, Zurawek D, Dziedzicka-Wasylewska M: Potential role of G protein-coupled receptor (GPCR) heterodimerization in neuropsychiatric disorders: Focus on depression. Pharmacol Rep, 2013, 65, 1498-1505.
32. Szczêsny E, OElusarczyk J, Glombik K, Budziszewska B, Kubera M, Lasoñ W, Basta-Kaim A: Possible contribution of IGF-1 to depressive disorder. Pharmacol Rep, 2013, 65, 1622-1631.
33. OEmialowska M, Szewczyk B, Woniak M, Wawrzak-Wlecial A, Domin H: Glial degeneration as a model of depression. Pharmacol Rep, 2013, 65, 1572-1579.
34. Varea E, Blasco-Ibáñez JM, Gómez-Climent MA, Castillo-Gómez E, Crespo C, Martínez-Guijarro FJ, Nácher J: Chronic fluoxetine treatment increases the expression of PSA-NCAM in the medial prefrontal cortex. Neuropsychopharmacology, 2007, 32, 803-812. (Pubitemid 46426182)
35. Varea E, Guirado R, Gilabert-Juan J, Martí U, Castillo-Gomez E, Blasco-Ibáñez JM, Crespo C, Nacher J: Expression of PSA-NCAM and synaptic proteins in the amygdala of psychiatric disorder patients. Psychiatr Res, 2012, 46: 189-197.
36. Vetulani J: Early maternal separation: A rodent model of depression and a prevailing human condition. Pharmacol Rep, 2013, 65, 1451-1461.
37. Volkow ND: The reality of comorbidity: Depression and drug abuse. Review Biol Psychiatry, 2004, 56, 714-717. (Pubitemid 39539824)
38. Vriend C, Raijmakers P, Veltman DJK, van Dijk KD, van der Werf YD, Foncke EM, Smit JH et al.: Depressive symptoms in Parkinson's disease are related to reduced [123I]FP-CIT binding in the caudate nucleus. J Neurol Neurosurg Psychiatry, 2013 [Epub ahead of print].
39. Watkins LR, Hutchinson MR, Johnston IN, Maier SF: Glia: Novel counter-regulators of opioid analgesia. Trends Neurosci, 2005, 28, 661-669. (Pubitemid 41654390)
40. Wêdzony K, Chocyk A, Maækowiak M. Potential roles of NCAM/PSA-NCAM proteins in depression and the mechanism of action of antidepressant drugs. Pharmacol Rep, 2013, 65, 1471-1478.
41. Zychowska M, Rojewska E, Przewlocka B, Mika J: Mechanisms and pharmacology of diabetic neuropathy-experimental and clinical studies. Pharmacol Rep, 2013, 65, 1601-1610.